Changes to the migratory inhibitory factor, IL-17, and IL-10 levels in serum from chronic hepatitis B patients and clinical significance following Baraclude® treatment

Abstract

ABSTRACT. This study aimed to determine the relationship between changes in the serum levels of macrophage migratory inhibitory factor (MIF), interleukin (IL) 17, and IL-10 during chronic hepatitis B treatment via Baraclude ® (Bristol-Meyers Squibb). Thirty-six patients with chronic hepatitis B and 24 healthy individuals were selected as the experimental and control groups, respectively, and the serum levels of MIF, IL-17, and IL-10 were measured during the period in which the experimental group was treated with oral Baraclude ® ; meanwhile, the alanine aminotransferase (ALT), hepatitis B virus (HBV) DNA, and HBV marker (M) levels were measured in the experimental group. In the experimental group, the ALT and HBV-DNA levels began to exhibit obvious decreases in week 4, and the MIF and IL-17 levels exhibited obvious increases in week 4 followed by gradual decreases; however, the IL-10 level exhibited an obvious decrease in week 12 and then (2015) increased gradually. These changes were significant when compared with the control group (P < 0.05). In conclusion, Baraclude ® treatment not only actively suppressed HBV but also indirectly balanced the MIF, IL-17, and IL-10 levels and reduced the liver inflammatory response.

Involvement of the Interleukin-23/Interleukin-17 Axis in Chronic Hepatitis C Virus Infection and Its Treatment Responses

“…IL-23, a member of the IL-12 cytokine family, is necessary for the survival and population expansion of Th17 cells [ 12 ] and responsible for inflammatory disorders through its downstream Th17 pathway [ 13 , 14 ]. Studies by Yu et al [ 15 ] have revealed that, in the hepatitis B virus (HBV) patients receiving antiviral therapy with Baraclude, there was a gradual decrease in the serum level of IL-17. Decreased HBV load was associated with decreased frequency of Treg cells, reduced level of IL-23, partially restored T cell immune response, and significant improvement of liver inflammation [ 16 ].…”

Change of Cytokines in Chronic Hepatitis B Patients and HBeAg are Positively Correlated with HBV RNA, Based on Real-world Study

“…37 , 38 It is also believed that the elevated serum level of IL-10 may be partly responsible for the poor clinical outcome of antiviral treatment. 39 Because IL-10 is a powerful immune and inflammatory inhibitory factor, it not only inhibits Th1 cellular immune response but also inhibits cytokines secreted from Th1 cells. 40 , 41 IL-10 could act on the early stage of dendritic cell maturation, inhibit the expression of costimulatory molecules, as well as reduce the expression of major histocompatibility antigen class II molecules, leading to the suppression of the maturation and differentiation of dendritic cells.…”